U.S. markets close in 21 minutes
  • S&P 500

    4,482.96
    +11.59 (+0.26%)
     
  • Dow 30

    35,235.01
    -59.75 (-0.17%)
     
  • Nasdaq

    15,008.14
    +110.80 (+0.74%)
     
  • Russell 2000

    2,268.50
    +2.84 (+0.13%)
     
  • Crude Oil

    82.49
    +0.21 (+0.26%)
     
  • Gold

    1,766.30
    -2.00 (-0.11%)
     
  • Silver

    23.26
    -0.09 (-0.38%)
     
  • EUR/USD

    1.1614
    +0.0013 (+0.12%)
     
  • 10-Yr Bond

    1.5840
    +0.0650 (+4.28%)
     
  • GBP/USD

    1.3732
    +0.0055 (+0.40%)
     
  • USD/JPY

    114.2860
    +0.6090 (+0.54%)
     
  • BTC-USD

    61,321.64
    +737.62 (+1.22%)
     
  • CMC Crypto 200

    1,430.90
    -20.74 (-1.43%)
     
  • FTSE 100

    7,203.83
    -30.20 (-0.42%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

Vensica Therapeutics Inks Strategic Partnership with Merz

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Vensica and Merz establish urology treatment platform

MISGAV, Israel, Aug. 11, 2021 /PRNewswire/ -- Vensica Therapeutics ("Vensica"), a clinical stage biopharmaceutical company, announced that it has signed a strategic collaboration agreement with Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins Vensica has licensed Merz's botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures. Merz has acquired an equity position in Vensica.

The Vensica Therapeutics device (courtesy Vensica Therapeutics)
The Vensica Therapeutics device (courtesy Vensica Therapeutics)

Vensica's needle-free platform for drug delivery, will be utilized for botulinum toxin type A delivery into the urinary bladder for the treatment of different urology indications including overactive bladder, neurogenic bladder, and interstitial cystitis. Today's gold standard treatment requires needle injections of the neurotoxin into the bladder wall. Vensica's needle-free platform makes for a far superior patient experience and resolves many needle-associated issues, including pain, urinary retention, and a generally more complicated procedure. The Vensica platform is expected to enable more efficacious treatment through more uniform delivery of the neurotoxin.

Vensica's distribution of its delivery device, combined with Merz's Xeomin® provides urologists with a full platform solution and enhanced patient experience.

Vensica CEO Avner Geva commented, "This agreement allows Vensica to accelerate our clinical trials and regulatory process. Additionally, the Vensica-Merz complete platform allows expansion of the number of urological indications that can be treated, including bladder cancer."

Vensica Chair, Nissim Darvish, M.D., Ph.D., added, "With the licensing of Xeomin®, a highly purified neurotoxin, we've achieved an important milestone for the company. Our unique, needle-free delivery system unlocks the potential of neurotoxins for urology and beyond."

"The collaboration with Vensica is a great example for our Merz Corporate Venture Capital Initiative," states Jörg Bergler, COO Merz Group. "Here, we are investing globally in companies who are pursuing innovative, breakthrough science. As an experienced partner, we are not only granting Vensica access to our toxin but also offer know-how and experience for the development and preparation of the regulatory approval process in an advisory capacity."

Stefan Brinkmann, CEO Merz Therapeutics: "This strategic, long-term partnership with Vensica allows us to expand into the attractive market of overactive bladder. It perfectly reflects the potential and capabilities of our neurotoxin platform for the development of sizeable non-movement disorder indications, pursuing our promise to create better outcomes for more patients. We strongly believe in the innovative and less invasive treatment of bladder diseases using Vensica's ultrasound-assisted delivery catheter and are therefore looking forward to bringing this new treatment option to the patients together with our partner Vensica."

About Vensica Therapeutics

Vensica is a urology therapeutics company based out of Israel. The company is developing a unique platform for drug delivery for several urinary bladder indications, based on a proprietary ultrasound-assisted drug delivery system. The company was founded in 2015 by Avner Geva, (Yale, B.Sc, Technion, M.Sc) and is led and backed by medical and therapeutics leaders, including chairman M.D., Ph.D, Nissim Darvish, Lew Pell, Laborie, The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), and The Israel Innovation Authority.

About Merz

Merz Group is a global, diversified company based in Frankfurt, Germany, with the three businesses Merz Aesthetics, Merz Therapeutics and Merz Consumer Care. The company is family-owned for over 112 years and is distinguished by its commitment to innovation, long-term perspective, and focus on profitable growth. In fiscal year 2019/20 (June 30), Merz generated revenue of EUR 981.5 million. The company employs 3,212 people in 28 countries worldwide. To learn more, please visit www.merz.com.

Contact:
Avner Geva, Chief Executive Officer
avner@vensica.com
Phone: 972-54-4959544

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/vensica-therapeutics-inks-strategic-partnership-with-merz-301352962.html

SOURCE Vensica Therapeutics